GlassScriptPhysician profile
Sean Devlin Bloor
NPI 1164981015
$7,529.49
in general payments reported to CMS, 2019-2025
47 companies · $2,742 in 2025
The $2,742 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $565 · 2023: $1,903 · 2024: $2,320 · 2025: $2,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,945 · Education: $19.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,944.81 |
| Education | $19.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,183.45 | 2022-2025 | Vraylar, Linzess, Ubrelvy |
| Viiv Healthcare Company | $965.89 | 2022-2025 | Apretude, Dovato, Cabenuva |
| Astrazeneca Pharmaceuticals LP | $769.94 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Gilead Sciences, INC. | $514.57 | 2022-2025 | Biktarvy |
| Amgen INC. | $412.65 | 2022-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $361.15 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Axsome Therapeutics, INC. | $274.32 | 2023-2025 | Auvelity, Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.08 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $248.93 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $242.52 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $199.68 | 2022-2025 | |
| Astellas Pharma US INC | $199.60 | 2022-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $135.45 | 2022-2025 | Trintellix |
| Corium, LLC | $134.55 | 2022-2024 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.72 | 2022-2025 | Xifaxan |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $105.97 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $98.99 | 2023-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $94.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Antares Pharma, INC. | $87.89 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Lundbeck LLC | $86.78 | 2024-2025 | Rexulti |
| Theratechnologies INC. | $84.90 | 2023-2025 | Egrifta, Trogarzo |
| Esperion Therapeutics, INC. | $76.80 | 2024-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $74.81 | 2022-2024 | Pifeltro, Delstrigo, Dificid |
| Abbott Laboratories | $73.67 | 2023-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $73.46 | 2024-2025 | Voquezna |
| Mayne Pharma Commercial LLC | $62.92 | 2024-2025 | |
| Glaxosmithkline, LLC. | $50.33 | 2022-2025 | Trelegy Ellipta |
| Bausch Health US, LLC | $49.76 | 2022-2023 | Aplenzin, Wellbutrin |
| Tolmar, INC. | $48.57 | 2025 | Jatenzo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.31 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $43.54 | 2022 | |
| Supernus Pharmaceuticals, INC. | $37.76 | 2022-2023 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $33.01 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $28.50 | 2023 | Quviviq |
| Tris Pharma INC | $25.99 | 2022-2023 | Dyanavel Xr |
| Optinose US, INC. | $23.88 | 2025 | |
| Dexcom, INC. | $23.69 | 2024 | Dexcom G6 Transmitter |
| Amphastar Pharmaceuticals, INC. | $20.15 | 2024 | |
| Endo Pharmaceuticals INC. | $19.82 | 2023 | Aveed |
| Vertex Pharmaceuticals Incorporated | $19.06 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $17.65 | 2023 | |
| Shield Therapeutics INC | $16.94 | 2025 | |
| Collegium Pharmaceutical, INC. | $16.88 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $16.50 | 2023 | Xarelto |
| Amneal Pharmaceuticals LLC | $15.29 | 2024 | Unithroid |
| Verity Pharmaceuticals INC. | $14.80 | 2025 | Tlando |
| Organon LLC | $10.47 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Bloor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.